IBD 50 Sep 2026

 STOCK ANALYSIS PROJECT · IBD 50 AS PUBLISHED · DATA THROUGH FRI SEP 25, 2026 CLOSE

IBD 50 Screen

All 50 names scored on fundamentals, trend and Monte Carlo risk, then the top five get a full workup: peer comparison, one-quarter and one-year forecasts with probabilities, and technical levels.

SPY $771.35 (-1.0% from high, 12M +17%)   ·   QQQ $744.5 (-0.6% from high, 12M +25%)   ·   IBD 50 avg 1Y vol 57% vs SPY 13%   ·   Avg MC P(up in 1Y) 56% vs SPY 73%

Top five from the screen

Ticker

Rating

Price

1Q target

P(≥ at 1Q)

1Y target

P(≥ at 1Y)

Score

MU  Micron Technology

BUY

$1,082

$1,180 (+9%)

43%

$1,300 (+20%)

45%

80 · #1

ECO  Okeanis Eco Tankers

HOLD

$77.90

$76.00 (-2%)

49%

$75.00 (-4%)

43%

79 · #2

NVDA  NVIDIA

BUY

$225.07

$245.00 (+9%)

36%

$290.00 (+29%)

32%

76 · #3

HALO  Halozyme Therapeutics

BUY

$113.90

$118.00 (+4%)

46%

$130.00 (+14%)

43%

75 · #4

INSW  International Seaways

HOLD

$105.64

$105.00 (-1%)

47%

$100.00 (-5%)

49%

72 · #5

Probabilities come from the Monte Carlo simulation under a market-neutral drift; see “How the numbers were built”. ECO and INSW targets are ex-dividend share prices.

Key takeaways

•      Two of five are crude tankers. ECO and INSW ride the same Iran-driven rate spike. Treat them as one position; own one, not both.

•      Micron reports Wed Sep 30. The 1Q forecast straddles a binary event. The 1-sigma daily move implied by its 79% volatility is about 5%, and earnings days often run 2–3× that.

•      Gold miners are resting, not broken. All nine precious-metal names are down 3–16% over the past month with RSI 44–53, yet every one still trades above its 200-day line.


 DEEP DIVE · HBM / DRAM MEMORY · SCREEN #1 OF 50 · IBD RANK 12

MU  Micron Technology

$1,082   BUY

The cheapest way to own AI data-center spend on forward earnings. Revenue is up 346% year over year, operating margin is 80%, and the stock trades under 7× next year's consensus EPS. The cycle, not the business, is the risk: memory multiples compress at peaks, and Wednesday's report sets the next leg.

Forecast and probability

 

1 quarter

1 year

Target price

$1,180

$1,300

Change from today

+9.0%

+20.1%

P(at or above target at horizon)

43%

45%

P(trades at target first)

77%

81%

MC median price

$1,104

$1,166

MC P10 – P90

$660 – $1,847

$423 – $3,209

P(down 20%+ at 1Y)

–

35%

1Y base case: about 8× forward EPS of roughly $160, or $1,300. Consensus mean is $1,516 from 46 analysts, but the range runs $361 to $2,200, which says the Street disagrees about where the cycle peaks. Simulation volatility 79%, drift +7.6% a year.

Monte Carlo price fan, next 12 months (log scale)

Technical analysis

One year, weekly closes with 50- and 200-day averages · trend checks 6/7

Uptrend intact: price is above the 20-, 50- and 200-day averages, RSI 63, MACD histogram positive. The 50-day has flattened (−1.6% over a month) after the June–July blow-off and a 39% peak-to-trough shakeout. Volume into earnings is light at 0.75× its 50-day average. First resistance is the 60-day high at $1,109, then the $1,255 record. Support sits at the 50-day ($942), then the $738 July low.

Key level

Value

Resistance

$1,109 · $1,255

Support

$942 (50d) · $738

Bollinger 20d

$882 – $1,106

RSI 14 / MACD

63 / positive

Off 52-wk high

−13.8%

Realized vol, 1Y

80.5%

Fundamentals

Metric

Value

Revenue, trailing 12 mo

$90.3B

Revenue growth y/y

+346%

Operating margin

80.4%

Return on equity

66.6%

Trailing / forward P/E

24.5× / 6.8×

PEG

0.16

Free cash flow, TTM

$7.6B

Cash / debt

$26.0B / $6.4B

Q4 FY26 guide (Sep 30)

$50B ±1B rev, $31 ±1 EPS

Analyst mean target (n)

$1,516 (46)

Peer comparison

Ticker

Price

Mkt cap

Fwd P/E

Rev growth

Op margin

3M

12M

1Y vol

To target

MU

$1,082

$1.22T

6.8×

+346%

+80%

-4%

+590%

81%

+40%

SNDK

$1,778

$260.3B

6.7×

+372%

+79%

-15%

+1731%

115%

+20%

WDC

$456.81

$164.7B

14.4×

+44%

+44%

-22%

+327%

80%

+46%

STX

$916.83

$208.5B

16.6×

+49%

+43%

+2%

+322%

75%

+23%

Memory and storage peers. SK Hynix and Samsung trade in Korea and are not shown. Micron matches SanDisk's single-digit forward multiple with a higher margin and far lower volatility, and it fell less than SNDK and WDC over the past three months.

Catalysts

•      Q4 FY26 report Wed Sep 30: guide was $50B revenue and $31 EPS; consensus sits near the top of that range

•      HBM4 now shipping into NVIDIA platforms; 2026 HBM supply sold out

•      16 long-term customer agreements with more than $22B of cash commitments through 2030

Risks

•      Guide-dependent: with consensus at the top of the range, an in-line Q1 FY27 outlook could sell off

•      Taiwan union demanding 15% of operating profit, with a strike vote in early October

•      Tariffs on semiconductors, Netlist DDR5 patent suit, and 3.3 beta to the S&P 500

Screen scorecard

Component

Score

Composite score

80 / 100

Fundamentals

39 / 40

Technicals

32 / 35

Risk

2 / 15

IBD rank

8 / 10

Beta to S&P 500

3.30


 

DEEP DIVE · VLCC / SUEZMAX CRUDE TANKERS · SCREEN #2 OF 50 · IBD RANK 2

ECO  Okeanis Eco Tankers

$77.90   HOLD

A pure play on spot VLCC rates, which spiked past $1 million a day on the Arabian Gulf–China route on Sep 16 as the Iran conflict disrupted shipping. Q2 was the best quarter in company history, and Q3 VLCC bookings near $207,000 a day point to another strong one. The question is how long the disruption lasts. The stock pays out about 90% of earnings, so most of the return arrives as cash rather than price.

Forecast and probability

 

1 quarter

1 year

Target price

$76.00

$75.00

Change from today

-2.4%

-3.7%

Est. total return incl. dividends

+5%

+18%

P(at or above target at horizon)

49%

43%

MC median price

$75.58

$68.72

MC P10 – P90

$57.03 – $100

$39.12 – $121

P(down 20%+ at 1Y)

–

41%

Targets are ex-dividend share prices. Expected total return is about +5% for the quarter and +18% for the year, including my dividend estimate of roughly $6 next quarter and $17 over 12 months. The single covering analyst targets $75. Simulation volatility 44%, drift -12.3% a year.

Monte Carlo price fan, next 12 months (log scale)

Technical analysis

One year, weekly closes with 50- and 200-day averages · trend checks 6/7

Momentum is rolling over. The stock spiked to $87.31 in mid-September with the rate headlines, then gave back 11%. Volume is 1.7× normal on the pullback, and the MACD histogram has turned negative. The trend is still up: price is above a steep 50-day ($66.8) and 200-day ($52). The upper Bollinger band at $88 marks the spike high; the lower band and 50-day at $63–67 are the first real support.

Key level

Value

Resistance

$87.3 (Sep high)

Support

$66.8 (50d) · $63.2 (BB)

Bollinger 20d

$63.2 – $88.3

RSI 14 / MACD

59 / negative

Off 52-wk high

−10.8%

Realized vol, 1Y

43.4%

Fundamentals

Metric

Value

Q2 2026 adj. EPS

$5.91

Q2 dividend (payout)

$5.25 (~90%)

Q3 VLCC days fixed

48% at ~$207k/day

Revenue growth y/y

+239%

Operating margin

75%

Trailing / forward P/E

7.2× / 13.1×

EV / EBITDA

7.4×

Fleet

18 ships, avg 5.6 yrs

Net loan-to-value

<25%

Analyst target (n)

$75 (1)

Peer comparison

Ticker

Price

Mkt cap

Fwd P/E

Rev growth

Op margin

3M

12M

1Y vol

To target

ECO

$77.90

$3.0B

13.1×

+239%

+75%

+56%

+164%

43%

-4%

INSW

$105.64

$5.2B

16.5×

+140%

+64%

+33%

+123%

39%

+1%

FRO

$47.73

$10.6B

10.4×

+97%

+66%

+34%

+107%

43%

+6%

TNK

$94.07

$3.3B

8.6×

+63%

+50%

+38%

+79%

39%

-0%

DHT

$21.78

$3.5B

10.2×

+96%

+71%

+23%

+77%

37%

+0%

STNG

$81.49

$4.1B

15.1×

+78%

+60%

+12%

+41%

36%

+19%

NAT

$7.72

$1.6B

17.0×

+98%

+52%

+32%

+141%

40%

-16%

ECO has the most VLCC spot leverage in the group and the strongest 3-month run. Frontline (FRO) is the larger, more liquid alternative. Most peers trade within a few percent of their consensus targets, which shows how far prices have run ahead of analyst models.

Catalysts

•      Q3 dividend declared with results in early November; which could exceed Q2's $5.25

•      Atlantic-to-Asia VLCC liftings up to about 35% of volume from 22%, which lengthens voyages

•      Winter seasonal strength on top of disruption

Risks

•      A ceasefire or reopened routes would cut rates quickly; forward P/E already assumes normalization

•      Heavy spot exposure: 52% of fleet days still open

•      Ex-dividend drops of $5–7 each quarter pull the share price down mechanically

Screen scorecard

Component

Score

Composite score

79 / 100

Fundamentals

32 / 40

Technicals

27 / 35

Risk

10 / 15

IBD rank

10 / 10

Beta to S&P 500

0.33


 DEEP DIVE · AI ACCELERATORS · SCREEN #3 OF 50 · IBD RANK 33

NVDA  NVIDIA

$225.07   BUY

Still the core AI holding, and now priced like a value stock on forward numbers: 14× next year's EPS with revenue doubling. Management guided fiscal 2028 revenue up about 70% on a supply-constrained basis. The stock is up 27% in a year while earnings more than doubled, which is what compressed the multiple.

Forecast and probability

 

1 quarter

1 year

Target price

$245.00

$290.00

Change from today

+8.9%

+28.8%

P(at or above target at horizon)

36%

32%

P(trades at target first)

63%

55%

MC median price

$230

$241

MC P10 – P90

$180 – $292

$150 – $394

P(down 20%+ at 1Y)

–

22%

1Y base case: about 18.5× forward EPS of $15.68, or $290. Consensus mean is $328 from 59 analysts. I sit below it because hyperscaler custom silicon caps the multiple. Simulation volatility 38%, drift +7.3% a year.

Monte Carlo price fan, next 12 months (log scale)

Technical analysis

One year, weekly closes with 50- and 200-day averages · trend checks 7/7

The cleanest chart in the top five: all seven trend checks pass. Price $225 sits over a rising 50-day ($216) and 200-day ($199.5). Bollinger bands have narrowed to $211–$233, a squeeze that usually resolves with a larger move. A weekly close above $236.5 would be a breakout to new highs. Below $216, look for $199–$190.

Key level

Value

Resistance

$234.8 · $236.5 (high)

Support

$216 (50d) · $199.5 (200d)

Bollinger 20d

$210.8 – $232.7

RSI 14 / MACD

55 / positive

Off 52-wk high

−4.8%

Realized vol, 1Y

37.6%

Fundamentals

Metric

Value

Revenue, trailing 12 mo

$303B

Revenue growth y/y

+106%

Q2 FY27 revenue

$96.2B (DC $89.0B)

Gross / operating margin

75.0% / 66.2%

Return on equity

117%

Trailing / forward P/E

28.5× / 14.4×

PEG

0.47

Q3 FY27 guide

$108B ±2%, GM 74%

Capital return, Q2

$20B buyback

Analyst mean target (n)

$328 (59)

Peer comparison

Ticker

Price

Mkt cap

Fwd P/E

Rev growth

Op margin

3M

12M

1Y vol

To target

NVDA

$225.07

$5.43T

14.4×

+106%

+66%

+17%

+27%

38%

+46%

AVGO

$352.81

$1.68T

18.2×

+86%

+54%

-3%

+6%

47%

+51%

TSM

$450.61

$2.34T

20.6×

+36%

+60%

+4%

+63%

40%

+23%

AMD

$630.63

$1.03T

40.5×

+50%

+17%

+21%

+291%

72%

-2%

MRVL

$261.94

$235.4B

38.8×

+37%

+17%

-2%

+215%

78%

+10%

INTC

$123.00

$650.2B

59.6×

+25%

+12%

-4%

+247%

76%

-5%

NVIDIA has the fastest growth and the lowest forward P/E in its peer group. AMD has tripled and now trades above its consensus target.

Catalysts

•      Q3 FY27 report Tue Nov 17; guide of $108B beat the $104B Street estimate

•      Vera Rubin began shipping in August, aimed at inference and agentic workloads

•      FY2028 revenue growth of about 70% guided as supply-constrained

Risks

•      Custom chips at Amazon, Alphabet, Microsoft and Meta displacing some workloads

•      Guide assumes zero China data-center revenue; policy could cut either way

•      $279B of supply commitments, mostly memory, if demand turns

Screen scorecard

Component

Score

Composite score

76 / 100

Fundamentals

33 / 40

Technicals

25 / 35

Risk

14 / 15

IBD rank

3 / 10

Beta to S&P 500

1.89


 

DEEP DIVE · DRUG-DELIVERY ROYALTIES · SCREEN #4 OF 50 · IBD RANK 10

HALO  Halozyme Therapeutics

$113.90   BUY

A royalty stream on subcutaneous versions of blockbuster biologics, priced at 11× forward earnings while growing revenue 48%. Q2 beat EPS by $0.49 and the August gap-up has held. The discount exists because the core ENHANZE patents run out later this decade. The newer MDASE platform, and the Keytruda subcutaneous fight with Merck, decide how much royalty life is left after that.

Forecast and probability

 

1 quarter

1 year

Target price

$118.00

$130.00

Change from today

+3.6%

+14.1%

P(at or above target at horizon)

46%

43%

P(trades at target first)

79%

74%

MC median price

$115

$122

MC P10 – P90

$90.50 – $151

$73.53 – $209

P(down 20%+ at 1Y)

–

23%

1Y base case: about 12.5× next year's EPS of $10.39, or $130. The consensus mean of $99.6 from 9 analysts sits below the price because targets have not caught up with the August rerating. Simulation volatility 41%, drift +7.7% a year.

Monte Carlo price fan, next 12 months (log scale)

Technical analysis

One year, weekly closes with 50- and 200-day averages · trend checks 6/7

A textbook flag after a breakaway gap. The stock jumped from about $86 to $103 in mid-August after the Q2 beat and has climbed steadily since. Bollinger bands are tight at $104–$115, and price sits 2.5% under its $116.85 high with RSI 64. Volume is running 1.4× normal. A close above $117 would confirm the next leg. The August gap ($86–$100) is support, and a fill would break the setup.

Key level

Value

Resistance

$116.85 (high)

Support

$99.7 (50d) · $86 (gap)

Bollinger 20d

$103.9 – $115.4

RSI 14 / MACD

64 / flat

Off 52-wk high

−2.5%

Realized vol, 1Y

36.4%

Fundamentals

Metric

Value

Q2 2026 revenue

$481M (+48% y/y)

Q2 EPS vs est.

$2.28 vs $1.79

FY26 EPS guidance

$8.65 – $9.00

Operating margin

59.8%

Gross margin

76.3%

Trailing / forward P/E

33.4× / 11.0×

EV / EBITDA

14.2×

New converts (Sep 17)

$1.3B, 1.50%, due 2033

Debt / cash

$2.18B / $0.23B

Analyst mean target (n)

$99.6 (9)

Peer comparison

Ticker

Price

Mkt cap

Fwd P/E

Rev growth

Op margin

3M

12M

1Y vol

To target

HALO

$113.90

$12.9B

11.0×

+48%

+60%

+52%

+54%

36%

-13%

RPRX

$58.21

$33.6B

10.2×

+17%

+20%

+4%

+66%

23%

+12%

INCY

$123.89

$25.1B

13.9×

+38%

+42%

+9%

+50%

33%

+3%

EXEL

$58.16

$14.4B

13.7×

+11%

+40%

+6%

+50%

37%

-8%

ARGX

$959.49

$59.7B

27.6×

+59%

+32%

+8%

+35%

34%

+23%

VRTX

$526.19

$133.4B

26.2×

+13%

+38%

+7%

+36%

28%

+8%

Royalty Pharma (RPRX) is the closest business model. HALO grows about 3× faster at a similar forward multiple, with triple the operating margin. argenx (ARGX) is also a HALO partner through Vyvgart Hytrulo.

Catalysts

•      Keytruda subcutaneous litigation with Merck: Munich court granted Halozyme a preliminary injunction in Dec 2025; the US case is ongoing

•      New ENHANZE and MDASE partner deals extend royalty life

•      Use of the $1.3B convert proceeds (buyback or acquisition)

Risks

•      ENHANZE patent expiries later this decade; the bear case is a royalty cliff

•      Litigation is binary; a loss against Merck removes a large optional upside

•      Convertible dilution and a leveraged balance sheet (debt/equity above 15×)

Screen scorecard

Component

Score

Composite score

75 / 100

Fundamentals

24 / 40

Technicals

31 / 35

Risk

13 / 15

IBD rank

8 / 10

Beta to S&P 500

0.52


 

DEEP DIVE · CRUDE AND PRODUCT TANKERS · SCREEN #5 OF 50 · IBD RANK 40

INSW  International Seaways

$105.64   HOLD

The lower-risk way to hold the tanker trade. INSW runs crude and product tankers, carries almost no net debt (about 6% of fleet value), and breaks even near $14,500 a day against Q3 bookings around $61,000. It pays out at least 85% of adjusted income. Q3 bookings are below Q2's $79,000, so the dividend likely steps down from $5.05.

Forecast and probability

 

1 quarter

1 year

Target price

$105.00

$100.00

Change from today

-0.6%

-5.3%

Est. total return incl. dividends

+4%

+9%

P(at or above target at horizon)

47%

49%

MC median price

$104

$98.66

MC P10 – P90

$81.00 – $133

$60.46 – $162

P(down 20%+ at 1Y)

–

35%

Targets are ex-dividend share prices. Expected total return is about +4% for the quarter and +9% for the year, including my dividend estimate of about $4.50 next quarter and $15 over 12 months. The consensus mean is $107 from 6 analysts. Simulation volatility 39%, drift -6.3% a year.

Monte Carlo price fan, next 12 months (log scale)

Technical analysis

One year, weekly closes with 50- and 200-day averages · trend checks 6/7

Similar to ECO but less extended. The stock set a record at $113.14 and pulled back 7% to $105.6. The MACD histogram is negative and volume is elevated at 1.46× normal. RSI is neutral at 56. The 50-day ($98.3) and lower Bollinger band ($97.3) form a clear support shelf, and the uptrend holds while price stays above it.

Key level

Value

Resistance

$111.7 (BB) · $113.1 (high)

Support

$98.3 (50d) · $97.3 (BB)

Bollinger 20d

$97.3 – $111.7

RSI 14 / MACD

56 / negative

Off 52-wk high

−6.6%

Realized vol, 1Y

38.6%

Fundamentals

Metric

Value

Q2 2026 adj. EPS

$5.91

Q2 adj. EBITDA / FCF

$345M / $261M

Q2 dividend

$5.05 (≥85% payout)

Q3 booked

48% of days at ~$61k/day

Operating margin

64.2%

Trailing / forward P/E

6.8× / 16.5×

EV / EBITDA

6.8×

Net debt / fleet value

~6%

Cash break-even

~$14.5k/day

Analyst mean target (n)

$107 (6)

Peer comparison

Ticker

Price

Mkt cap

Fwd P/E

Rev growth

Op margin

3M

12M

1Y vol

To target

INSW

$105.64

$5.2B

16.5×

+140%

+64%

+33%

+123%

39%

+1%

ECO

$77.90

$3.0B

13.1×

+239%

+75%

+56%

+164%

43%

-4%

FRO

$47.73

$10.6B

10.4×

+97%

+66%

+34%

+107%

43%

+6%

TNK

$94.07

$3.3B

8.6×

+63%

+50%

+38%

+79%

39%

-0%

STNG

$81.49

$4.1B

15.1×

+78%

+60%

+12%

+41%

36%

+19%

DHT

$21.78

$3.5B

10.2×

+96%

+71%

+23%

+77%

37%

+0%

Teekay Tankers (TNK), also in the IBD 50, holds net cash and trades at 8.6× forward. It is the cheapest name in the group, but it lacks INSW's product-tanker mix.

Catalysts

•      Q3 results and dividend in early November

•      Product-tanker strength (MRs near $35k/day) diversifies away from VLCC spot

•      10 LR1 newbuilds ordered at pre-inflation prices for 2028 delivery

Risks

•      Same geopolitical driver as ECO; rates would normalize together

•      Q3 rates already below Q2, so earnings are past their peak

•      Consensus forward P/E of 16.5× implies EPS roughly halves

Screen scorecard

Component

Score

Composite score

72 / 100

Fundamentals

30 / 40

Technicals

27 / 35

Risk

14 / 15

IBD rank

2 / 10

Beta to S&P 500

0.30


Full screen, all 50

Sorted by composite score. Top-five picks are highlighted. Trend = number of 7 trend checks passed. MC range = 1-year P5 / median / P95 as a multiple of today's price.

#

Ticker

Name

Theme

Score

IBD

EPS %

Sales %

Price

3M

12M

Off high

RSI

Trend

Vol

Fwd P/E

To target

P(up 1Y)

P(−25%)

MC 1Y P5 / P50 / P95

1

MU

Micron Technology

AI hardware

80

12

999+

346

$1,082

-4%

+590%

-14%

63

6/7

81%

6.8×

+40%

53%

33%

0.29 / 1.06 / 4.03×

2

ECO

Okeanis Eco Tankers

Tankers

79

2

612

185

$77.90

+56%

+164%

-11%

59

6/7

43%

13.1×

-4%

57%

21%

0.52 / 1.08 / 2.23×

3

NVDA

NVIDIA

AI hardware

76

33

112

106

$225.07

+17%

+27%

-5%

55

7/7

38%

14.4×

+46%

57%

17%

0.58 / 1.07 / 2.03×

4

HALO

Halozyme Therapeutics

Health care

75

10

48

48

$113.90

+52%

+54%

-3%

64

6/7

36%

11.0×

-13%

56%

19%

0.57 / 1.06 / 2.11×

5

INSW

International Seaways

Tankers

72

40

479

130

$105.64

+33%

+123%

-7%

56

6/7

39%

16.5×

+1%

59%

18%

0.56 / 1.09 / 2.05×

6

ETON

Eton Pharmaceuticals

Health care

71

1

450

99

$57.68

+62%

+186%

-13%

53

6/7

66%

22.4×

+23%

53%

32%

0.31 / 1.06 / 4.03×

7

WT

WisdomTree

Other

70

3

72

57

$24.33

+42%

+72%

-6%

59

6/7

40%

18.0×

+4%

58%

19%

0.55 / 1.09 / 2.14×

8

NTAP

NetApp

Software

70

17

66

30

$201.15

+32%

+67%

-4%

60

7/7

43%

18.1×

-2%

57%

20%

0.54 / 1.08 / 2.22×

9

TGTX

TG Therapeutics

Health care

70

18

-71

70

$57.43

+3%

+66%

-3%

58

7/7

45%

19.4×

+21%

57%

21%

0.51 / 1.07 / 2.29×

10

ERO

Ero Copper

Metals & mining

66

5

80

74

$37.87

+43%

+106%

-7%

59

7/7

64%

7.9×

+8%

56%

29%

0.37 / 1.08 / 3.04×

11

HNGE

Hinge Health

Health care

66

8

69

53

$95.57

+21%

+87%

-1%

60

6/7

55%

31.3×

+13%

55%

25%

0.46 / 1.07 / 2.44×

12

TNK

Teekay Tankers

Tankers

64

45

294

121

$94.07

+38%

+79%

-9%

52

6/7

39%

8.6×

-0%

57%

18%

0.56 / 1.07 / 2.07×

13

SN

SharkNinja

Other

62

19

30

22

$177.74

+23%

+68%

-9%

57

7/7

43%

23.2×

+18%

57%

20%

0.55 / 1.07 / 2.16×

14

ARGX

argenx

Health care

60

34

96

59

$959.49

+8%

+35%

-11%

45

5/7

34%

27.6×

+23%

57%

18%

0.57 / 1.08 / 2.08×

15

TSM

Taiwan Semiconductor

AI hardware

60

36

62

24

$450.61

+4%

+63%

-6%

62

6/7

40%

20.6×

+23%

59%

18%

0.56 / 1.09 / 2.09×

16

AUGO

Aura Minerals

Metals & mining

59

6

156

76

$83.57

+30%

+154%

-24%

50

5/7

74%

10.3×

+22%

55%

31%

0.32 / 1.09 / 3.79×

17

ANET

Arista Networks

AI hardware

59

14

40

38

$206.55

+31%

+44%

-4%

60

7/7

54%

39.8×

+17%

55%

26%

0.44 / 1.07 / 2.60×

18

SLDE

Slide Insurance

Other

59

31

89

17

$23.10

+21%

+53%

-14%

45

5/7

41%

6.3×

+12%

56%

20%

0.55 / 1.07 / 2.13×

19

WPM

Wheaton Precious Metals

Metals & mining

58

23

90

85

$142.92

+26%

+33%

-14%

46

6/7

51%

28.7×

+25%

57%

23%

0.47 / 1.10 / 2.48×

20

RBRK

Rubrik

Software

57

11

767

38

$109.55

+52%

+34%

-6%

60

7/7

65%

142.7×

+10%

54%

30%

0.35 / 1.07 / 3.31×

21

SCCO

Southern Copper

Metals & mining

57

13

71

41

$203.92

+21%

+80%

-8%

55

7/7

52%

28.0×

-16%

55%

24%

0.47 / 1.07 / 2.48×

22

EXEL

Exelixis

Health care

57

38

21

11

$58.16

+6%

+50%

-3%

56

6/7

37%

13.7×

-8%

59%

15%

0.61 / 1.08 / 1.95×

23

AMD

Advanced Micro Devices

AI hardware

56

9

246

50

$630.63

+21%

+291%

-1%

73

5/7

72%

40.5×

-2%

55%

30%

0.34 / 1.09 / 3.50×

24

ZETA

Zeta Global

Software

56

16

386

44

$29.45

+55%

+45%

-10%

49

6/7

66%

24.4×

+7%

55%

27%

0.40 / 1.08 / 2.96×

25

NEM

Newmont

Metals & mining

56

21

47

15

$121.43

+26%

+45%

-10%

48

6/7

50%

11.9×

+13%

57%

22%

0.50 / 1.09 / 2.33×

26

SMCI

Super Micro Computer

AI hardware

56

24

315

93

$43.26

+41%

-6%

-26%

64

6/7

95%

8.1×

-2%

53%

35%

0.23 / 1.06 / 4.54×

27

IAG

Iamgold

Metals & mining

55

22

223

48

$19.70

+24%

+67%

-21%

50

5/7

65%

8.3×

+24%

55%

28%

0.40 / 1.08 / 2.93×

28

GH

Guardant Health

Health care

54

7

n/a

44

$177.25

+19%

+195%

-3%

59

7/7

56%

n/m

+11%

55%

25%

0.46 / 1.08 / 2.66×

29

FNV

Franco-Nevada

Metals & mining

54

46

46

57

$257.87

+20%

+21%

-10%

50

6/7

39%

27.6×

+11%

57%

17%

0.58 / 1.07 / 1.98×

30

SNOW

Snowflake

Software

53

27

77

35

$335.94

+35%

+52%

-13%

55

6/7

62%

111.5×

+27%

56%

25%

0.46 / 1.08 / 2.73×

31

DXCM

DexCom

Health care

53

28

46

13

$86.62

+24%

+27%

-6%

49

6/7

40%

27.7×

+9%

58%

18%

0.56 / 1.08 / 2.07×

32

GRMN

Garmin

Other

53

39

29

11

$294.14

+27%

+24%

-6%

63

7/7

34%

26.4×

+3%

58%

16%

0.59 / 1.08 / 1.98×

33

ARIS

Aris Mining

Metals & mining

52

20

74

60

$18.93

+25%

+102%

-19%

50

4/7

64%

6.4×

+96%

55%

28%

0.38 / 1.09 / 3.02×

34

RGLD

Royal Gold

Metals & mining

52

32

41

115

$252.49

+21%

+31%

-18%

53

4/7

42%

19.6×

+22%

59%

17%

0.57 / 1.08 / 2.02×

35

PAYC

Paycom Software

Software

52

50

35

10

$220.46

+71%

+3%

-10%

51

6/7

46%

15.8×

-1%

56%

24%

0.46 / 1.08 / 2.61×

36

NTRA

Natera

Health care

51

4

n/a

38

$412.56

+57%

+152%

-1%

84

5/7

47%

n/m

-14%

55%

23%

0.48 / 1.07 / 2.42×

37

MGNI

Magnite

Software

51

48

30

17

$23.97

+28%

+7%

-11%

51

6/7

58%

18.6×

+20%

55%

26%

0.42 / 1.07 / 2.66×

38

LITE

Lumentum

AI hardware

50

25

267

109

$941.65

+15%

+492%

-13%

54

7/7

97%

27.3×

+22%

53%

35%

0.22 / 1.07 / 5.40×

39

PLTR

Palantir Technologies

Software

50

42

156

93

$189.67

+68%

+6%

-9%

64

7/7

59%

81.7×

+3%

54%

29%

0.38 / 1.06 / 3.12×

40

VEEV

Veeva Systems

Health care

49

47

18

18

$280.68

+64%

+0%

-10%

67

6/7

42%

27.4×

+6%

56%

21%

0.52 / 1.07 / 2.25×

41

SITM

SiTime

AI hardware

46

41

398

127

$662.27

-2%

+125%

-27%

58

5/7

84%

44.4×

+28%

54%

33%

0.25 / 1.09 / 4.73×

42

NET

Cloudflare

Software

45

15

38

36

$349.02

+47%

+60%

-5%

62

7/7

66%

208.2×

-4%

56%

28%

0.38 / 1.09 / 2.96×

43

DDOG

Datadog

Software

45

29

41

36

$268.13

+12%

+96%

-8%

67

6/7

68%

90.2×

+7%

53%

30%

0.36 / 1.06 / 3.31×

44

AU

AngloGold Ashanti

Metals & mining

45

37

57

27

$99.03

+21%

+51%

-23%

44

4/7

61%

9.9×

+18%

55%

26%

0.41 / 1.08 / 2.78×

45

CAI

Caris Life Sciences

Health care

44

35

100

45

$31.98

+73%

+8%

-5%

74

6/7

67%

85.2×

-12%

53%

31%

0.34 / 1.05 / 3.31×

46

ESTC

Elastic

Software

44

49

17

15

$88.12

+57%

+4%

-18%

53

5/7

58%

22.3×

+26%

56%

27%

0.40 / 1.08 / 2.87×

47

AEM

Agnico Eagle Mines

Metals & mining

43

44

57

35

$194.48

+24%

+22%

-24%

49

4/7

49%

15.6×

+11%

57%

22%

0.49 / 1.09 / 2.39×

48

BLLN

BillionToOne

Health care

38

43

999+

64

$123.08

+4%

–

-18%

66

5/7

96%

82.9×

+1%

55%

35%

0.18 / 1.13 / 5.64×

49

OUST

Ouster

AI hardware

37

30

n/a

56

$43.72

+4%

+53%

-32%

64

5/7

104%

n/m

+36%

53%

37%

0.17 / 1.08 / 6.70×

50

TEM

Tempus AI

Health care

31

26

n/a

22

$85.01

+51%

+10%

-19%

73

5/7

72%

n/m

-19%

52%

34%

0.29 / 1.05 / 4.18×

Score = fundamentals 40 (IBD EPS and sales growth, operating margin, ROE, forward P/E, analyst upside) + technicals 35 (7-point trend template and 6-month return per unit of volatility) + risk 15 (Monte Carlo odds of a 30% drawdown) + IBD rank 10. Each input is a percentile within the 50. Trend checks: price above 50-day, 50-day above 200-day, price above 200-day, 50-day rising, within 15% of 52-week high, RSI 45–72, MACD histogram positive.


How the numbers were built

Prices and fundamentals. Two years of daily bars and current valuation fields from Yahoo Finance, pulled Sep 27, 2026. IBD rank, EPS % change and sales % change come from the IBD 50 list supplied; IBD caps EPS change at 999%.

Monte Carlo. 20,000 one-year daily paths for each top-five stock (8,000 for the screen). Daily shocks are bootstrapped from the stock's own last 252 log returns, demeaned so past momentum does not leak into the forecast, then rescaled to a volatility that blends 1-year and 3-month realized vol. This keeps the fat tails of the real return distribution.

Drift. A market-neutral 8% a year, minus the expected dividend yield for the two tankers (ECO 20%, INSW 14%), since their share price drops on each ex-date. The probabilities answer: if the stock only earns a market-like return, how likely is it to reach the target by chance and volatility alone?

Forecast targets. Base case for each stock, set from forward earnings, a multiple the market is likely to pay, and where consensus sits. Consensus targets lag price, so they carry less weight for names that have just rerated.

Two probability measures. “At horizon” is the share of paths at or above the target on the last day of the quarter or year. “Touch” is the share that trade at or above it at any point first, which matters if you would sell into the target.

Limits. Bootstrapped volatility cannot foresee regime breaks: a ceasefire that collapses tanker rates, a memory-price downturn, or a patent ruling. Tanker dividend estimates are estimates, not company guidance. This is research to support your own decisions, not investment advice.

Sources

Investing.com — Micron earnings outlook ahead of Sep 30 — https://www.investing.com/news/stock-market-news/micron-earnings-outlook-what-to-watch-ahead-of-the-september-30-report-93CH-4911385

TradingKey — Micron Q4 earnings preview — https://www.tradingkey.com/analysis/stocks/us-stocks/262188101-mu-dram-hbm-skhynix-samsung-tradingkey

Webull — Nvidia Q2 FY2027 results and Q3 guide — https://www.webull.com/blog/304-Nvidia-Q2-FY2027-Earnings-Beats-Revenue-EPS-Estimates-Guides-Q3-to-108B

Motley Fool — Is Nvidia a buy in September 2026? — https://www.fool.com/investing/2026/09/15/is-nvidia-stock-a-buy-in-september-2026/

Yahoo Finance — Oil tanker rates top $1 million a day — https://finance.yahoo.com/markets/commodities/articles/oil-tanker-rates-top-1-123500215.html

Yahoo Finance — Okeanis Eco Tankers Q2 call highlights — https://finance.yahoo.com/markets/stocks/articles/okeanis-eco-tankers-q2-earnings-050348781.html

Yahoo Finance — International Seaways Q2 2026 call — https://finance.yahoo.com/markets/stocks/articles/international-seaways-insw-q2-2026-144401730.html

ad-hoc-news — Halozyme Q2 growth and convertible notes — https://www.ad-hoc-news.de/boerse/news/nebenwerte/halozyme-stock-falls-2-34-percent-after-strong-quarterly-growth/70171343

pharmaphorum — German court blocks Keytruda SC launch — https://pharmaphorum.com/news/setback-msd-german-court-blocks-keytruda-sc-launch

Yahoo Finance — price history, quotes and financial data (Sep 27, 2026) — https://finance.yahoo.com/


Comments

Popular posts from this blog